4 results
Primary objective:To evaluate the objective response rate (ORR) of AZD1775 in combination with gemcitabine, carboplatin, paclitaxel,or PLD in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancerSecondary…
To evaluate the safety and efficacy of PRX-102 in patients with Fabry disease currently treated with agalsidase alfa
The primary objective of the study is:* To evaluate the overall safety and tolerability related to systemic plasminogen activation of single doses of HisproUK (part 1) and sequential administration of tPA and HisproUK (part 2)The secondary…
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.